Press release
Zevra Therapeutics Expands Executive Leadership Team
Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"Rahsaan W. Thompson appointed as Chief Legal Officer, Secretary and Compliance Officer Alison Peters appointed as Chief People Officer CELEBRATION, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced the appointments of Rahsaan W. Thompson as Chief Legal Officer, Secretary and Compliance Officer, and Alison Peters as Chief People Officer. Both Mr. Thompson and Ms. Peters bring deep expertise in building high-performing teams which will be essential to deliver success through the Company's next phase of growth. “We are thrilled to welcome both Rahsaan and Alison to the Zevra team as we continue the expansion and progress of our rare disease portfolio,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra. “Their roles will be instrumental to driving our evolution into a leading rare disease therapeutics company.” Mr. Thompson’s extensive experience handling domestic and international agreements and transactions, alongside his skills in litigation, government affairs, SEC compliance, and commercial management, make him well-poised to serve as Chief Legal Officer for Zevra. Ms. Peters brings a wealth of experience in executive coaching, culture design, and HR operations, making her an invaluable addition to our leadership team with a track record of high performance through progressive people strategies. Combined, their expertise in talent management and legal affairs will be instrumental as we continue to grow our commercial capabilities and advance the development of our rare disease assets. “I am thrilled to join Zevra on their mission to provide novel therapeutics for unmet rare disease needs,” expressed Rahsaan Thompson. “I look forward to leveraging my diverse experience to support Zevra’s continued success.” Mr. Thompson brings more than 25 years of experience as a business leader and attorney in the biotech industry. Mr. Thompson, previously the Chief Legal Officer at Lyell Immunopharma, a publicly traded and clinical-stage biotech corporation, has extensive experience handling corporate governance, clinical studies, intellectual property, licensing arrangements, and litigation, among other responsibilities. His knowledge of financing plans and partnerships as well as regulatory and compliance matters...